De novo myocardial regeneration: advances and pitfalls

• Published in: Antioxidants & redox signaling Vol. 13; no. 12; p. 1867
• Main Authors: Haider, Khawaja Husnain, Buccini, Stephanie, Ahmed, Rafeeq P H, Ashraf, Muhammad
• Format: Journal Article
• Language: English
• Published: United States 15.12.2010
• Subjects: Cardiomyopathies - therapy; Cell- and Tissue-Based Therapy - methods; Embryonic Stem Cells - cytology; Humans; Induced Pluripotent Stem Cells - cytology; Myocardium - cytology; Pluripotent Stem Cells - cytology; Stem Cell Transplantation
• ISSN: 1557-7716
• DOI: 10.1089/ars.2010.3388

The capability of adult tissue-derived stem cells for cardiogenesis has been extensively studied in experimental animals and clinical studies for treatment of postischemic cardiomyopathy. The less-than-anticipated improvement in the heart function in most clinical studies with skeletal myoblasts and bone marrow cells has warranted a search for alternative sources of stem cells. Despite their multilineage differentiation potential, ethical issues, teratogenicity, and tissue rejection are main obstacles in developing clinically feasible methods for embryonic stem cell transplantation into patients. A decade-long research on embryonic stem cells has paved the way for discovery of alternative approaches for generating pluripotent stem cells. Genetic manipulation of somatic cells for pluripotency genes reprograms the cells to pluripotent status. Efforts are currently focused to make reprogramming protocols safer for clinical applications of the reprogrammed cells. We summarize the advancements and complicating features of stem cell therapy and discuss the decade-and-a-half-long efforts made by stem cell researchers for moving the field from bench to the bedside as an adjunct therapy or as an alternative to the contemporary therapeutic modalities for routine clinical application. The review also provides a special focus on the advancements made in the field of somatic cell reprogramming.